← All trials
NCT04747392
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 19, 2020
- Primary completion
- Oct 30, 2020
- Completion date
- Nov 11, 2020
- First posted
- Feb 10, 2021
- Last posted
- Feb 10, 2021
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.